File Download
  Links for fulltext
     (May Require Subscription)

Article: Improved Cell Survival and Paracrine Capacity of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells Promote Therapeutic Potential for Pulmonary Arterial Hypertension.

TitleImproved Cell Survival and Paracrine Capacity of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells Promote Therapeutic Potential for Pulmonary Arterial Hypertension.
Authors
KeywordsEmbryonic stem cell-derived mesenchymal stem cells
Pulmonary arterial hypertension
Issue Date2012
PublisherCognizant Communication Corp. The Journal's web site is located at https://www.cognizantcommunication.com/journal-titles/cell-transplantation
Citation
Cell Transplantation, 2012, v. 21 n. 10, p. 2225-2239 How to Cite?
AbstractAlthough transplantation of adult bone marrow mesenchymal stem cells (BM-MSCs) holds promise in the treatment for pulmonary arterial hypertension (PAH), the poor survival and differentiation potential of adult BM-MSCs have limited their therapeutic efficiency. Here, we compared the therapeutic efficacy of human embryonic stem cell-derived MSCs (hESC-MSCs) with adult BM-MSCs for the treatment of PAH in an animal model. One week following monocrotaline (MCT)-induced PAH, mice were randomly assigned to receive phosphate-buffered saline (MCT group); 3.0×106 human BM-derived MSCs (BM-MSCs group) or 3.0 ×106 hESC-derived MSCs (hESC-MSCs group) via tail vein injection. At 3 weeks posttransplantation, the right ventricular systolic pressure (RVSP), degree of RV hypertrophy, and medial wall thickening of pulmonary arteries were lower=, and pulmonary capillary density was higher in the hESC-MSC group as compared with BM-MSC and MCT groups (all p < 0.05). At 1 week posttransplantation, the number of engrafted MSCs in the lungs was found significantly higher in the hESC-MSC group than in the BM-MSC group (all p < 0.01). At 3 weeks posttransplantation, implanted BM-MSCs were undetectable whereas hESC-MSCs were not only engrafted in injured pulmonary arteries but had also undergone endothelial differentiation. In addition, protein profiling of hESC-MSC- and BM-MSC-conditioned medium revealed a differential paracrine capacity. Classification of these factors into bioprocesses revealed that secreted factors from hESC-MSCs were preferentially involved in early embryonic development and tissue differentiation, especially blood vessel morphogenesis. We concluded that improved cell survival and paracrine capacity of hESC-MSCs provide better therapeutic efficacy than BM-MSCs in the treatment for PAH. © 2012 Cognizant Comm. Corp.
Persistent Identifierhttp://hdl.handle.net/10722/159623
ISSN
2015 Impact Factor: 3.427
2015 SCImago Journal Rankings: 1.161
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhang, Yen_US
dc.contributor.authorLiao, Sen_US
dc.contributor.authorYang, Men_US
dc.contributor.authorLiang, Xen_US
dc.contributor.authorPoon, MWen_US
dc.contributor.authorWong, CYen_US
dc.contributor.authorWang, Jen_US
dc.contributor.authorZhou, Zen_US
dc.contributor.authorCheong, SKen_US
dc.contributor.authorLee, CNen_US
dc.contributor.authorTse, HFen_US
dc.contributor.authorLian, Qen_US
dc.date.accessioned2012-08-16T05:53:29Z-
dc.date.available2012-08-16T05:53:29Z-
dc.date.issued2012en_US
dc.identifier.citationCell Transplantation, 2012, v. 21 n. 10, p. 2225-2239en_US
dc.identifier.issn0963-6897-
dc.identifier.urihttp://hdl.handle.net/10722/159623-
dc.description.abstractAlthough transplantation of adult bone marrow mesenchymal stem cells (BM-MSCs) holds promise in the treatment for pulmonary arterial hypertension (PAH), the poor survival and differentiation potential of adult BM-MSCs have limited their therapeutic efficiency. Here, we compared the therapeutic efficacy of human embryonic stem cell-derived MSCs (hESC-MSCs) with adult BM-MSCs for the treatment of PAH in an animal model. One week following monocrotaline (MCT)-induced PAH, mice were randomly assigned to receive phosphate-buffered saline (MCT group); 3.0×106 human BM-derived MSCs (BM-MSCs group) or 3.0 ×106 hESC-derived MSCs (hESC-MSCs group) via tail vein injection. At 3 weeks posttransplantation, the right ventricular systolic pressure (RVSP), degree of RV hypertrophy, and medial wall thickening of pulmonary arteries were lower=, and pulmonary capillary density was higher in the hESC-MSC group as compared with BM-MSC and MCT groups (all p < 0.05). At 1 week posttransplantation, the number of engrafted MSCs in the lungs was found significantly higher in the hESC-MSC group than in the BM-MSC group (all p < 0.01). At 3 weeks posttransplantation, implanted BM-MSCs were undetectable whereas hESC-MSCs were not only engrafted in injured pulmonary arteries but had also undergone endothelial differentiation. In addition, protein profiling of hESC-MSC- and BM-MSC-conditioned medium revealed a differential paracrine capacity. Classification of these factors into bioprocesses revealed that secreted factors from hESC-MSCs were preferentially involved in early embryonic development and tissue differentiation, especially blood vessel morphogenesis. We concluded that improved cell survival and paracrine capacity of hESC-MSCs provide better therapeutic efficacy than BM-MSCs in the treatment for PAH. © 2012 Cognizant Comm. Corp.-
dc.languageengen_US
dc.publisherCognizant Communication Corp. The Journal's web site is located at https://www.cognizantcommunication.com/journal-titles/cell-transplantation-
dc.relation.ispartofCell Transplantationen_US
dc.rightsCell Transplantation. Copyright © Cognizant Communication Corp.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectEmbryonic stem cell-derived mesenchymal stem cells-
dc.subjectPulmonary arterial hypertension-
dc.titleImproved Cell Survival and Paracrine Capacity of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells Promote Therapeutic Potential for Pulmonary Arterial Hypertension.en_US
dc.typeArticleen_US
dc.identifier.emailPoon, MW: ilmwpoon@hku.hken_US
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_US
dc.identifier.emailLian, Q: qzlian@hkucc.hku.hken_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.identifier.authorityLian, Q=rp00267en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3727/096368912X653020-
dc.identifier.pmid22776744-
dc.identifier.scopuseid_2-s2.0-84870377755-
dc.identifier.hkuros202668en_US
dc.identifier.hkuros215868-
dc.identifier.volume21en_US
dc.identifier.eissn1555-3892-
dc.identifier.isiWOS:000313227300011-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats